CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda

• Published in: Cell journal (Yakhteh) Vol. 26; no. 2; pp. 150 - 157
• Main Authors: Parvini, Neda, Akbari, Mohammad Esmaeil, Hamidieh, Amir Ali, Fathi, Fardin, Amini, Abbas Ali, Ebrahimi, Marzieh, Vahabzadeh, Zakaria
• Format: Journal Article
• Language: English
• Published: Iran Royan Institute of Iran 01.02.2024; Royan Institute (ACECR), Tehran
• Subjects: Acute lymphoblastic leukemia; Anticancer properties; Blocking; Blood; Cancer; Cancer immunotherapy; Carbon dioxide; Cell surface; ctla-4; CTLA-4 protein; Cytotoxicity; Flow cytometry; Granzyme B; Immunotherapy; Interleukin 15; Leukemia; Leukocytes (mononuclear); Lymphocytes; Lymphocytes T; nalm-6; Natural killer cells; NKG2 antigen; Peripheral blood mononuclear cells; Purity; γ-Interferon; CTLA-4; Natural Killer Cells; Immunotherapy; Nalm-6
• ISSN: 2228-5806; 2228-5814
• DOI: 10.22074/cellj.2024.2015187.1444

There is interest in using cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy to treat blood cancers. Unfortunately, patients with acute lymphoblastic leukaemia (ALL) frequently exhibit resistance to treatment and natural killer (NK) cell exhaustion. This study aims to increase the cytotoxic potency of natural killer cells by using CTLA-4 to block the Nalm-6 leukaemia cell line. In this experimental study, NK cells were purified from the peripheral blood mononuclear cells (PBMCs) of 10 healthy people and assessed by flow cytometry for purity and viability. The purified cells were activated overnight at 37°C and 5% CO2 with interleukin-15 (IL-15, 10 ng/ml) followed by evaluation of expressions of CTLA-4, activating and inhibitory receptors, and the release of interferon gamma (IFN-γ) and granzyme B (GZM B). CTLA-4 expression on NK cells from recurrent ALL patients was also evaluated. Finally, the cytotoxic activity of NK cells was assessed after the CTLA-4 blockade. The purity of the isolated cells was 96.58 ± 2.57%. Isolated NK cells activated with IL-15 resulted in significantly higher CTLA-4 expression (8.75%, P<0.05). Similarly, CTLA-4 expression on the surface of NK cells from patients with ALL was higher (7.46%) compared to healthy individuals (1.46%, P<0.05). IL-15 reduced NKG2A expression (P<0.01), and increased expressions of NKP30 (P<0.05) and NKP46 (P<0.01). The activated NK cells released more IFN-γ (P<0.5) and GZM B (P<0.01) compared to unactivated NK cells. Blockade of CTLA-4 enhanced the NK cell killing potential against Nalm-6 cells (56.3%, P<0.05); however, IFN-γ and GZM B levels were not statistically different between the blocked and non-blocked groups. Our findings suggest that CTLA-4 blockage of Nalm-6 cells causes an increase in antitumour activity of NK cells against these cells. Our study also provides evidence for the potential of cancer immunotherapy treatment using blocking anti-CTLA-4 mAbs.